Literature DB >> 25916278

Anti-edema effect of melatonin on spinal cord injury in rats.

Xinwei Liu1, Yu Wang1, Jishun Yang2, Yunen Liu3, Dapeng Zhou1, Mingxiao Hou3, Liangbi Xiang1.   

Abstract

AIM: To determine the anti-edema effects of melatonin on spinal cord injury (SCI) in rats.
METHODS: A total of 150 adult male Sprague-Dawley rats were randomly allocated to the following three groups (n=50): a sham group which underwent laminectomy without dural compression; an SCI group, which underwent laminectomy followed by SCI and received saline i.p. immediately after injury and then daily for 2 days; an MT group, which underwent laminectomy followed by SCI and received a 100 mg/kg dose of melatonin i.p. immediately after SCI and then daily for 2 days. The cords were removed at 12, 24, 48 and 72 h after surgery in every group. Spinal cord edema was evaluated by determining the spinal cord water content. Expressions of AQP4 and GFAP positive cells in injured spinal cord were detected by immunohistochemical staining, and protein expressions of AQP4 and GFAP were detected by Western blotting.
RESULTS: Spinal cord water content was obviously increased after SCI, which was maintained almost unchanged by melatonin treatment (100 mg/kg) at 12 h after injury but was significantly reduced from 24 h to 72 h. The expressions of AQP4 and GFAP increased in the injured spinal cord segments, which were decreased by melatonin treatment (100 mg/kg) between 24 h and 72 h after SCI.
CONCLUSIONS: Melatonin (100 mg/kg) had anti-edema effects after acute SCI probably by down-regulating the expression level of AQP4 protein, and it may eliminate astrocytic swelling after SCI through down-regulating the expression level of GFAP protein.

Entities:  

Keywords:  edema; melatonin; rats; spinal cord injury

Mesh:

Substances:

Year:  2015        PMID: 25916278     DOI: 10.5507/bp.2015.012

Source DB:  PubMed          Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub        ISSN: 1213-8118            Impact factor:   1.245


  7 in total

1.  The role of AQP3 and AQP4 channels in cisplatin-induced cardiovascular edema and the protective effect of melatonin.

Authors:  Lokman Koral; Mehmet Akif Ovali; Nezahat Kubra Tufekcioglu; Ersen Karakilic; Yasemen Adali; Metehan Uzun
Journal:  Mol Biol Rep       Date:  2021-10-16       Impact factor: 2.316

2.  Concentrated Growth Factors (CGF) Combined with Melatonin in Guided Bone Regeneration (GBR): A Case Report.

Authors:  Alessandro Leonida; Gaia Favero; Paolo Caccianiga; Saverio Ceraulo; Luigi Fabrizio Rodella; Rita Rezzani; Gianluigi Caccianiga
Journal:  Diagnostics (Basel)       Date:  2022-05-18

3.  Inhibition of HMGB1 reduces rat spinal cord astrocytic swelling and AQP4 expression after oxygen-glucose deprivation and reoxygenation via TLR4 and NF-κB signaling in an IL-6-dependent manner.

Authors:  Lin Sun; Man Li; Xun Ma; Haoyu Feng; Junlai Song; Cong Lv; Yajun He
Journal:  J Neuroinflammation       Date:  2017-11-25       Impact factor: 8.322

Review 4.  Melatonin for the treatment of spinal cord injury.

Authors:  Yan Zhang; Wen-Xiu Zhang; Yan-Jun Zhang; Ya-Dong Liu; Zong-Jian Liu; Qi-Chao Wu; Yun Guan; Xue-Ming Chen
Journal:  Neural Regen Res       Date:  2018-10       Impact factor: 5.135

5.  Experimental Treatments for Oedema in Spinal Cord Injury: A Systematic Review and Meta-Analysis.

Authors:  Emma Masterman; Zubair Ahmed
Journal:  Cells       Date:  2021-10-07       Impact factor: 6.600

Review 6.  Elevated intraspinal pressure in traumatic spinal cord injury is a promising therapeutic target.

Authors:  Chao-Hua Yang; Zheng-Xue Quan; Gao-Ju Wang; Tao He; Zhi-Yu Chen; Qiao-Chu Li; Jin Yang; Qing Wang
Journal:  Neural Regen Res       Date:  2022-08       Impact factor: 5.135

Review 7.  Mechanisms of ginsenosides exert neuroprotective effects on spinal cord injury: A promising traditional Chinese medicine.

Authors:  Le Qi; Jun Zhang; Jinghong Wang; Junyan An; Wu Xue; Qinyi Liu; Yan Zhang
Journal:  Front Neurosci       Date:  2022-08-23       Impact factor: 5.152

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.